ArticleFrontiers in oncology2026
Comparison of Gd-EOB-DTPA-enhanced MRI versus multiphasic enhanced CT for detecting occult recurrence after curative ablation of hepatocellular carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the value of Gd-EOB-DTPA-enhanced MRI in the early diagnosis of occult intrahepatic recurrence after curative ablation for hepatocellular carcinoma (HCC). Materials and methods: This retrospective study included 74 HCC patients who underwent curative microwave ablation, divided into a CT group and a CT+MRI group. An expert committee determined recurrence via consensus readout. Diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and the area under the receiver operating characteristic curve (AUROC) of the two imaging methods were compared through blinded image review. Results: With a median follow-up of 23.5 months, 38 patients (51.4%) were diagnosed with recurrence. Within the CT+MRI group, the sensitivity of Gd-EOB-DTPA-enhanced MRI for diagnosing recurrent patients was significantly higher than that of enhanced CT (P < 0.05), leading to altered BCLC stages in 2 patients. Low signal intensity on the hepatobiliary phase was the most sensitive finding. Diagnostic performance analysis confirmed that the AUROC and sensitivity of Gd-EOB-DTPA-enhanced MRI were significantly superior to those of enhanced CT (all P < 0.05). Conclusion: Gd-EOB-DTPA-enhanced MRI demonstrated superior diagnostic performance compared with multiphasic contrast-enhanced CT for detecting CT-occult intrahepatic recurrence after curative MWA. However, because MRI was selectively performed in patients with high-risk features, elevated AFP, or equivocal CT findings, its benefit is best interpreted as an adjunctive tool in this targeted population rather than a routine replacement for CT surveillance. A risk-stratified follow-up strategy may optimize clinical benefit and cost-effectiveness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.